This research study is studying a drug called eribulin combined with standard treatment as a
possible preoperative treatment for HER2 negative inflammatory breast cancer.
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational intervention to learn whether the intervention works
in treating a specific disease. "Investigational" means that the intervention is being
Eribulin works by interfering with cancer cell division, growth, and spread.
The goal of this research study is to evaluate inflammatory breast cancer's response to
treatment with eribulin followed by AC chemotherapy (Cohort A) and also the response to
treatment with AC followed by Eribulin (Cohort B) when given as a preoperative chemotherapy
treatment for participants with HER2 negative inflammatory breast cancer.
Inflammatory Breast Cancer,
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,
inflammatory breast cancers
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.